Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1628 1629
This examiner grants 67% of resolved cases
Theodore R. Howell is an examiner in Tech Center 1600, Art Unit 1624. With 1023 resolved cases, he has a significant track record and an allowance rate of 66.8%. This rate suggests a consistent and relatively predictable prosecution environment. The median days to allowance is 945, which is a key metric for applicants in this tech center. The volume of 1023 resolved cases ensures these figures are statistically significant.
The interview lift for this examiner is 25.3%. This lift indicates that interviews are a useful strategy to improve upon the 66.8% allowance rate. Given the 945 median days to allowance, the examiner maintains a relatively efficient pace for successful applications. Practitioners should view the 25.3% lift as a reliable tool for advancing cases that may be stalled in written prosecution. The 66.8% allowance rate provides a solid baseline for success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18793023 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE | Non-Final OA | Genentech, Inc. |
| 17990661 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS | Final Rejection | The Regents of the University of California |
| 18376127 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18107336 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 19319520 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS TO IMPROVE HEART FUNCTION IN A HUMAN | Non-Final OA | AXCESS GLOBAL SCIENCES, LLC |
| 18747316 | FXR (NR1H4) MODULATING COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 19236838 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 18512551 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Final Rejection | AXSOME THERAPEUTICS, INC. |
| 18503996 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Final Rejection | AXSOME THERAPEUTICS, INC. |
| 18366992 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Final Rejection | AXSOME THERAPEUTICS, INC. |
| 18745626 | METHOD OF TREATING PAIN OR INTERSTITIAL CYSTITIS USING INDOLE COMPOUND | Non-Final OA | Japan Tobacco Inc. |
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | Final Rejection | The United States Government as represented by The Department of Veterans Affairs |
| 18671916 | TERPENE-BASED COMPOSITIONS, PROCESSES, METHODOLOGIES FOR CREATION AND PRODUCTS THEREBY | Non-Final OA | Scientific Holdings, LLC |
| 18671814 | TERPENE-BASED COMPOSITIONS, PROCESSES, METHODOLOGIES FOR CREATION AND PRODUCTS THEREBY | Non-Final OA | Scientific Holdings, LLC |
| 18671969 | TERPENE-BASED COMPOSITIONS, PROCESSES, METHODOLOGIES FOR CREATION AND PRODUCTS THEREBY | Non-Final OA | Scientific Holdings, LLC |
| 18530143 | TERPENE-BASED COMPOSITIONS, METHODOLGIES FOR CREATION AND PRODUCTS THEREBY | Non-Final OA | Scientific Holdings, LLC |
| 18530198 | TERPENE-BASED COMPOSITIONS, PROCESSES, METHODOLOGIES FOR CREATION AND PRODUCTS THEREBY | Non-Final OA | Scientific Holdings, LLC |
| 18638371 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | Non-Final OA | PIKSci Inc. |
| 18682329 | LOCAL TOPICAL FORMULATION CONTAINING JAK INHIBITOR OR SALT THEREOF OR CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | ZHUHAI UNITED LABORATORIES CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy